Success Metrics

Clinical Success Rate
90.0%

Based on 27 completed trials

Completion Rate
90%(27/30)
Active Trials
5(12%)
Results Posted
26%(7 trials)
Terminated
3(7%)

Phase Distribution

Ph early_phase_1
4
10%
Ph not_applicable
15
36%
Ph phase_1
8
19%
Ph phase_2
11
26%
Ph phase_3
2
5%
Ph phase_4
2
5%

Phase Distribution

12

Early Stage

11

Mid Stage

4

Late Stage

Phase Distribution42 total trials
Early Phase 1First-in-human
4(9.5%)
Phase 1Safety & dosage
8(19.0%)
Phase 2Efficacy & side effects
11(26.2%)
Phase 3Large-scale testing
2(4.8%)
Phase 4Post-market surveillance
2(4.8%)
N/ANon-phased studies
15(35.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

27 of 30 finished

Non-Completion Rate

10.0%

3 ended early

Currently Active

5

trials recruiting

Total Trials

42

all time

Status Distribution
Active(5)
Completed(27)
Terminated(3)
Other(7)

Detailed Status

Completed27
unknown7
Recruiting4
Terminated3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
42
Active
5
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (9.5%)
Phase 18 (19.0%)
Phase 211 (26.2%)
Phase 32 (4.8%)
Phase 42 (4.8%)
N/A15 (35.7%)

Trials by Status

completed2764%
unknown717%
terminated37%
recruiting410%
active_not_recruiting12%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT07559656Not Applicable

Oxytocin's Effects on Real Time-fMRI Neurofeedback Training of Anterior Insula Activity

Recruiting
NCT07551882Phase 2

Oxytocin Plus Self-compassion Training in Borderline Personality Disorder

Recruiting
NCT07227454Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Recruiting
NCT07053774Phase 2

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Recruiting
NCT06605300Not Applicable

The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

Completed
NCT03185819Phase 2

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Completed
NCT02682225Phase 1

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Completed
NCT05892939Not Applicable

Effects of Intranasal Oxytocin on Fear Processing in Naturalistic Contexts

Completed
NCT05896553Not Applicable

Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction

Completed
NCT05312008Phase 2

Does Oxytocin Alter Tolerance to or Motivation for Alcohol

Terminated
NCT06405737Not Applicable

Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

Completed
NCT03566069Phase 2

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

Active Not Recruiting
NCT05245708Not Applicable

Effects of Oxytocin on Reinforcement Learning and Interoception

Completed
NCT03908567Phase 2

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery

Completed
NCT05920707Not Applicable

Common and Differentiated Representations Between Social Exclusion and Social Separation

Unknown
NCT02149823Phase 1

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

Terminated
NCT05532501Not Applicable

The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes

Unknown
NCT05206149Phase 4

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

Completed
NCT03016598Phase 2

Stimulant Oxytocin Study

Completed
NCT01900301Phase 1

Generalization of Extinction Learning

Completed

Drug Details

Intervention Type
DRUG
Total Trials
42